News headlines about Palatin Technologies (NYSE:PTN) have trended positive recently, according to Alpha One. Alpha One, a service of Accern, rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Palatin Technologies earned a daily sentiment score of 0.30 on Alpha One’s scale. Alpha One also assigned media stories about the biopharmaceutical company an impact score of 93 out of 100, indicating that recent press coverage is extremely likely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have effected AlphaOne’s scoring:
- Palatin Technologies, Inc. (PTN) noted a price change of 0.46% and … – Stocks Gallery (stocksgallery.com)
- Hailiang Education Group Inc. (:HLG) and Palatin Technologies, Inc. (:PTN) Slow Out of The Gate – Geneva Journal (genevajournal.com)
- The Short Interest in Palatin Technologies, Inc. (PTN) Increases By … – BangaloreWeekly (bangaloreweekly.com)
- Investors Set Sail on Valuation For Palatin Technologies, Inc. (AMEX:PTN) – Stock Talker (thestocktalker.com)
Palatin Technologies (NYSE:PTN) remained flat at $0.35 during mid-day trading on Friday. 1,418,945 shares of the company traded hands. The firm’s 50 day moving average is $0.40 and its 200 day moving average is $0.42. Palatin Technologies has a 12 month low of $0.29 and a 12 month high of $0.90. The stock’s market capitalization is $53.48 million.
Palatin Technologies (NYSE:PTN) last released its earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.10 by $0.12. The firm had revenue of $10.82 million for the quarter, compared to analyst estimates of $60 million. During the same quarter in the prior year, the business posted ($0.01) earnings per share. Analysts predict that Palatin Technologies will post ($0.06) EPS for the current fiscal year.
Separately, Canaccord Genuity reissued a “buy” rating and issued a $6.00 target price on shares of Palatin Technologies in a research note on Thursday, June 1st.
About Palatin Technologies
Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.
Receive News & Ratings for Palatin Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.